Unknown

Dataset Information

0

Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020.


ABSTRACT:

Background

Clinical trials suggest lower rates of major bleeding with direct-acting oral anticoagulants (DOACs) than with warfarin, but anticoagulant-related bleeding remains one of the most common outpatient adverse drug events.

Methods

We estimated the number of emergency department (ED) visits and subsequent hospitalizations for oral anticoagulant-related bleeding in 2016-2020 based on active surveillance in a nationally representative, size-stratified probability sample of 60 U.S. hospitals. We estimated rates of ED visits using a nationally-projected retail prescription dispensing database.

Results

Based on 19,557 cases, oral anticoagulant-related bleeding resulted in an estimated 1,270,259 (95 % Confidence Interval [CI], 644,686-1,895,832) ED visits for the five years 2016-2020, of which 47.8 % (95 % CI, 40.6 %-55.0 %) resulted in hospitalization. Oral anticoagulant-related bleeding resulted in an estimated 230,163 (95% CI, 109,598-350,728) ED visits in 2016 and 301,433 (95% CI, 138,363-464,503) in 2020. During 2016-2020, ED visits for DOAC-related bleeding increased by an average of 27.9 % (95 % CI, 24.0 %-32.0 %; p < .001) per year, while ED visits for warfarin-related bleeding decreased by an average of 8.8 % (95 % CI, -10.7 % to -7.0 %; p = .001) per year. The estimated rate of bleeding visits per 100 patients dispensed oral anticoagulants at least once in 2016-2020 was highest for patients aged ≥ 80 years (13.1; 95 % CI, 6.2-20.0) and lowest for those aged <45 years (4.0; 95 % CI, 2.6-5.5); it was 5.9 visits per 100 patients dispensed DOACs [95 % CI, 2.5-9.2] and 13.0 visits per 100 patients dispensed warfarin [95 % CI, 7.4-18.7].

Conclusions

Although the rates of ED visits for anticoagulant-related bleeding may be lower for DOACs than for warfarin, persistently large numbers of patients requiring ED visits for anticoagulant-related bleeding despite increased use of DOACs and declining use of warfarin suggest that efforts to improve appropriate prescribing and monitoring of anticoagulants remain important.

SUBMITTER: Geller AI 

PROVIDER: S-EPMC10870325 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020.

Geller Andrew I AI   Shehab Nadine N   Lovegrove Maribeth C MC   Weidle Nina J NJ   Budnitz Daniel S DS  

Thrombosis research 20230329


<h4>Background</h4>Clinical trials suggest lower rates of major bleeding with direct-acting oral anticoagulants (DOACs) than with warfarin, but anticoagulant-related bleeding remains one of the most common outpatient adverse drug events.<h4>Methods</h4>We estimated the number of emergency department (ED) visits and subsequent hospitalizations for oral anticoagulant-related bleeding in 2016-2020 based on active surveillance in a nationally representative, size-stratified probability sample of 60   ...[more]

Similar Datasets

| S-EPMC10155071 | biostudies-literature
| S-EPMC10590093 | biostudies-literature
| S-EPMC10841721 | biostudies-literature
| S-EPMC4996794 | biostudies-literature
| S-EPMC10667469 | biostudies-literature
| S-EPMC8910124 | biostudies-literature
| S-EPMC10249045 | biostudies-literature
| S-EPMC9925333 | biostudies-literature
| S-EPMC10546289 | biostudies-literature
| S-EPMC6475457 | biostudies-literature